Most Read Articles
Jairia Dela Cruz, 6 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, Yesterday
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.
06 Sep 2020
Type 2 diabetes mellitus patients taking proton pump inhibitors (PPIs) are at a higher risk of sustaining hip fractures, a recent study has found.

New oral therapies for adolescents with HCV more cost-effective than PR strategy

21 Jun 2020
Authorities in Malaysia have approved a compulsory license for Hepatitis C treatment, which allows for cheaper generic medication to be produced without the drug patent holder’s consent.

Novel oral regimens for adolescents with hepatitis C virus (HCV) appears to be cost-effective compared with pegylated interferon α with ribavirin (PR) therapies, but only in the context of China and the US, suggests a recent study.

This analysis sought to assess the cost-effectiveness of oral regimens relative to that of PR strategies in adolescents in the US and China.

The investigators developed a Markov model to measure the economic and health outcomes of ledipasvir/sofosbuvir (LS) for genotypes 1 and 4, sofosbuvir/ribavirin (SR) for genotype 2, and ledipasvir/sofosbuvir/ribavirin (LSR) for genotype 3 HCV infection compared with the outcomes of PR treatment. They obtained clinical costs and utility inputs from published sources.

The following outcomes were measured: lifetime discounted quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). One-way and probabilistic sensitivity analyses facilitated the uncertainty.

In the US, the ICERs of LS treatment were $14,699/QALY for genotype 1 HCV infection and $14,946/QALY for genotype 4 in comparison to the PR strategy. Additionally, the ICER of SR strategy was $42,472/QALY for genotype 2, while that of LSR was $49,409/QALY for genotype 3.

In the Chinese context, LS for genotypes 1 and 4, SR for genotype 2, and LSR for genotype 3 were the major alternative treatments to the PR strategy. Of note, these results were robust to sensitivity analyses.

“Novel oral regimes have been approved for treating HCV infection in adolescents due to their superior effectiveness and safety,” the investigators noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 6 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, Yesterday
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.
06 Sep 2020
Type 2 diabetes mellitus patients taking proton pump inhibitors (PPIs) are at a higher risk of sustaining hip fractures, a recent study has found.